{"id":411629,"date":"2021-01-11T06:33:13","date_gmt":"2021-01-11T11:33:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411629"},"modified":"2021-01-11T06:33:13","modified_gmt":"2021-01-11T11:33:13","slug":"affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/","title":{"rendered":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\u20ac10 million available at closing and up to \u20ac15 million available upon achievement of certain milestones<\/li>\n<\/ul>\n<p>\n        <strong>Heidelberg, Germany, January 11, 2021 \u2013<\/strong> Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has entered into a debt financing agreement with Silicon Valley Bank German Branch (SVB) which provides Affimed with up to \u20ac25 million in term loans.<\/p>\n<p>\u201cWe are pleased to continue our relationship with Silicon Valley Bank,\u201d commented Angus Smith, Chief Financial Officer of Affimed. \u201cThis financing will help support the broad development strategy for our ICE\u00ae molecules as monotherapies and in combination with natural killer cells and checkpoint inhibitors.\u201d<\/p>\n<p>\u201cWe\u2019re delighted to continue our support for Affimed and its mission to develop cancer treatments using its proprietary ICE\u00ae platform,\u201d said Nooman Haque, Head of Life Sciences &amp; Healthcare SVB EMEA. \u201cFor decades SVB has worked with leading life sciences companies to improve their chances of success.\u201d<\/p>\n<p>\u201cThe completion of this transaction is another important milestone in the continuing growth of SVB\u2019s activities in Germany and we\u2019re proud to continue our relationship with one of the landmark biopharma companies in the market,\u201d added Oscar Jazdowski, General Manager, SVB German Branch said.<\/p>\n<p>Pursuant to the terms of the agreement, Silicon Valley Bank will make loans of up to \u20ac25 million available in three tranches: \u20ac10 million available at closing, an additional \u20ac7.5 million upon the achievement of certain conditions, including milestones related to Affimed\u2019s pipeline and market capitalization, and a third tranche of \u20ac7.5 million upon the achievement of certain additional conditions related to Affimed\u2019s pipeline and liquidity. The loans will bear interest at the greater of the European Central Bank Base Rate and 0%, plus 5.5%, and Affimed is entitled to make interest only payments through December 1, 2022, or June 1, 2023 if Affimed draws on the third tranche of the loans. The loans will mature at the end of November 2025. There are no financial covenants in the agreement. Proceeds will be used to fund research and development expenses for Affimed\u2019s expanding pipeline and for working capital purposes.<\/p>\n<p>\n        <strong>About Affimed N.V.<\/strong>\n      <\/p>\n<p>Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed\u2019s fit-for-purpose ROCK\u00ae platform allows innate cell engagers to be designed for specific patient populations. Affimed is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed\/refractory peripheral T cell lymphoma and into a Phase 1\/2a dose escalation\/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=suvKy6cMNu84klovfupvLCwwuXCsvDws0VY9dyf12CdsxQEN_QGY9ysR8kv-VInIwIhh_6H1muTmfC_gztg-mQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.affimed.com<\/u><\/a>.<\/p>\n<p>\n        <strong>FORWARD-LOOKING STATEMENTS<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of our ICE\u00ae molecules, the value of our ROCK\u00ae platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading \u201cRisk Factors\u201d in Affimed\u2019s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong>\n      <\/p>\n<p>Alexander Fudukidis<br \/>Head of Investor Relations<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B0DkUdi_3qkQaxjml16Ur2FeKZ3NdMeTcSz2eQEl42j_vAuV4JCLxk1-QZ56Pjx1HQEfwrbcZSf6S41a5My8pr9YFTpPEF-3xqD_ftbzbp0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>a.fudukidis@affimed.com<\/u><\/a><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Mary Beth Sandin <br \/>Head of Marketing and Communications<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c8RTZ5Nk-dih9zIk3soQ2ADoji4_NSQzATEjtf3wo7JLMyBoFaMH7WX5HeVOKNxzWTSsgpg3vP83k51z-Yk6-yo6mV09_Ir4qzY7LntS0lE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>m.sandin@affimed.com<\/u><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/9bed432c-0cf3-4452-9ffc-9bf8a64b1963\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u20ac10 million available at closing and up to \u20ac15 million available upon achievement of certain milestones Heidelberg, Germany, January 11, 2021 \u2013 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has entered into a debt financing agreement with Silicon Valley Bank German Branch (SVB) which provides Affimed with up to \u20ac25 million in term loans. \u201cWe are pleased to continue our relationship with Silicon Valley Bank,\u201d commented Angus Smith, Chief Financial Officer of Affimed. \u201cThis financing will help support the broad development strategy for our ICE\u00ae molecules as monotherapies and in combination with natural killer cells and checkpoint inhibitors.\u201d \u201cWe\u2019re delighted to continue our support &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u20ac10 million available at closing and up to \u20ac15 million available upon achievement of certain milestones Heidelberg, Germany, January 11, 2021 \u2013 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has entered into a debt financing agreement with Silicon Valley Bank German Branch (SVB) which provides Affimed with up to \u20ac25 million in term loans. \u201cWe are pleased to continue our relationship with Silicon Valley Bank,\u201d commented Angus Smith, Chief Financial Officer of Affimed. \u201cThis financing will help support the broad development strategy for our ICE\u00ae molecules as monotherapies and in combination with natural killer cells and checkpoint inhibitors.\u201d \u201cWe\u2019re delighted to continue our support &hellip; Continue reading &quot;Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank\",\"datePublished\":\"2021-01-11T11:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/\"},\"wordCount\":731,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/\",\"name\":\"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\",\"datePublished\":\"2021-01-11T11:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk","og_description":"\u20ac10 million available at closing and up to \u20ac15 million available upon achievement of certain milestones Heidelberg, Germany, January 11, 2021 \u2013 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has entered into a debt financing agreement with Silicon Valley Bank German Branch (SVB) which provides Affimed with up to \u20ac25 million in term loans. \u201cWe are pleased to continue our relationship with Silicon Valley Bank,\u201d commented Angus Smith, Chief Financial Officer of Affimed. \u201cThis financing will help support the broad development strategy for our ICE\u00ae molecules as monotherapies and in combination with natural killer cells and checkpoint inhibitors.\u201d \u201cWe\u2019re delighted to continue our support &hellip; Continue reading \"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:33:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank","datePublished":"2021-01-11T11:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/"},"wordCount":731,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/","name":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==","datePublished":"2021-01-11T11:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDAyMiM0MDA4NTAwMzAjMjAwMzczNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-e25-million-debt-financing-agreement-with-silicon-valley-bank\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}